Literature DB >> 28472900

The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia.

Donald C Goff1, Peter Falkai1, W Wolfgang Fleischhacker1, Ragy R Girgis1, Rene M Kahn1, Hiroyuki Uchida1, Jingping Zhao1, Jeffrey A Lieberman1.   

Abstract

Concerns have been raised that treatment with antipsychotic medication might adversely affect long-term outcomes for people with schizophrenia. The evidence cited for these concerns includes the association of antipsychotic treatment with brain volume reduction and with dopamine receptor sensitization, which might make patients vulnerable to relapse and illness progression. An international group of experts was convened to examine findings from clinical and basic research relevant to these concerns. Little evidence was found to support a negative long-term effect of initial or maintenance antipsychotic treatment on outcomes, compared with withholding treatment. Randomized controlled trials strongly support the efficacy of antipsychotics for the acute treatment of psychosis and prevention of relapse; correlational evidence suggests that early intervention and reduced duration of untreated psychosis might improve longer-term outcomes. Strategies for treatment discontinuation or alternative nonpharmacologic treatment approaches may benefit a subgroup of patients but may be associated with incremental risk of relapse and require further study, including the development of biomarkers that will enable a precision medicine approach to individualized treatment.

Entities:  

Keywords:  Antipsychotics; Schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 28472900     DOI: 10.1176/appi.ajp.2017.16091016

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  40 in total

1.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

2.  Progress in Schizophrenia Research and Treatment.

Authors: 
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

3.  The long-term treatment of schizophrenia with antipsychotics: a perennial debate.

Authors:  W Wolfgang Fleischhacker
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

4.  Effects of the T-type calcium channel antagonist Z944 on paired associates learning and locomotor activity in rats treated with the NMDA receptor antagonist MK-801.

Authors:  Andrew J Roebuck; Wendie N Marks; Max C Liu; Nimra B Tahir; Nadine K Zabder; Terrance P Snutch; John G Howland
Journal:  Psychopharmacology (Berl)       Date:  2018-09-24       Impact factor: 4.530

5.  Five Year Outcomes of Tapering Antipsychotic Drug Doses in a Community Mental Health Center.

Authors:  Sandra Steingard
Journal:  Community Ment Health J       Date:  2018-08-03

6.  "It's When the Trees Blossom": Explanatory Beliefs, Stigma, and Mental Illness in the Context of HIV in Botswana.

Authors:  Timothy D Becker; Ari R Ho-Foster; Ohemaa B Poku; Shathani Marobela; Haitisha Mehta; Dai Thi Xuan Cao; Lyla S Yang; Lilo I Blank; Vincent Ikageng Dipatane; Letumile Rogers Moeng; Keneilwe Molebatsi; Marlene M Eisenberg; Frances K Barg; Michael B Blank; Philip Renison Opondo; Lawrence H Yang
Journal:  Qual Health Res       Date:  2019-02-09

7.  A Prospective Longitudinal Investigation of Cortical Thickness and Gyrification in Schizophrenia.

Authors:  Eric A Nelson; Nina V Kraguljac; David M White; Ripu D Jindal; Ah L Shin; Adrienne C Lahti
Journal:  Can J Psychiatry       Date:  2020-02-05       Impact factor: 4.356

8.  Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.

Authors:  Hideaki Tani; Shotaro Takasu; Hiroyuki Uchida; Takefumi Suzuki; Masaru Mimura; Hiroyoshi Takeuchi
Journal:  Neuropsychopharmacology       Date:  2019-11-26       Impact factor: 7.853

9.  What a Clinician Should Know About the Neurobiology of Schizophrenia: A Historical Perspective to Current Understanding.

Authors:  Lynn E DeLisi
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

10.  Association of Hippocampal Atrophy With Duration of Untreated Psychosis and Molecular Biomarkers During Initial Antipsychotic Treatment of First-Episode Psychosis.

Authors:  Donald C Goff; Botao Zeng; Babak A Ardekani; Erica D Diminich; Yingying Tang; Xiaoduo Fan; Isaac Galatzer-Levy; Chenxiang Li; Andrea B Troxel; Jijun Wang
Journal:  JAMA Psychiatry       Date:  2018-04-01       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.